Literature DB >> 19308656

Low burden of a JAK2-V617F mutated clone in monoclonal haematopoiesis in a Japanese woman with Budd-Chiari syndrome.

Kohtaro Toyama1, Masamitsu Karasawa2, Arito Yamane2, Hiromi Koiso2, Akihiko Yokohama2, Hideki Uchiumi2, Takayuki Saitoh2, Hiroshi Handa2, Ken Sato3, Hitoshi Takagi3, Shuichi Miyawaki4, Hirokazu Murakami2, Yoshihisa Nojima2, Norifumi Tsukamoto2.   

Abstract

Approximately one-half of the cases of Budd-Chiari syndrome (BCS) are caused by bcr/abl negative chronic myeloproliferative disorders (CMPDs). Furthermore, a mutation in the Janus kinase protein (JAK2-V617F) is detected in half of the patients with BCS. However, whether the JAK2 mutation is the primary event leading to CMPDs and BCS is controversial. We present a report concerning a young woman who suffered from BCS prior to the onset of CMPDs. Analysis of X-chromosome inactivation patterns in this patient, using the human androgen receptor gene demonstrated monoclonal haematopoiesis in her granulocytes. In contrast, she had a low burden of a JAK2-V617F mutation positive clone among granulocyte populations. These results suggest that the JAK2-V617F mutation occurs after the onset of monoclonal haematopoiesis; thus the V617F mutation of JAK2 may not be the primary event in the induction of BCS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19308656     DOI: 10.1007/s12185-009-0280-y

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  27 in total

1.  The factor V Leiden mutation and the prothrombin G20210A mutation was not found in Japanese patients with pulmonary thromboembolism.

Authors:  A Ro; M Hara; A Takada
Journal:  Thromb Haemost       Date:  1999-12       Impact factor: 5.249

2.  The JAK2(V617F) mutation may be present several years before the occurrence of overt myeloproliferative disorders.

Authors:  C Bellanné-Chantelot; P Jego; P Lionne-Huyghe; M Tulliez; A Najman
Journal:  Leukemia       Date:  2007-09-13       Impact factor: 11.528

3.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

Review 4.  Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis.

Authors:  V De Stefano; L Teofili; G Leone; J J Michiels
Journal:  Semin Thromb Hemost       Date:  1997       Impact factor: 4.180

5.  Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome.

Authors:  Raj K Patel; Nicholas C Lea; Michael A Heneghan; Nigel B Westwood; Dragana Milojkovic; Murugaiyan Thanigaikumar; Deborah Yallop; Roopen Arya; Antonio Pagliuca; Joop Gäken; Julia Wendon; Nigel D Heaton; Ghulam J Mufti
Journal:  Gastroenterology       Date:  2006-06       Impact factor: 22.682

6.  Prevalence of the factor V Leiden mutation in hepatic and portal vein thrombosis.

Authors:  A E Mahmoud; E Elias; N Beauchamp; J T Wilde
Journal:  Gut       Date:  1997-06       Impact factor: 23.059

Review 7.  Antiphospholipid syndrome as the second cause of non-tumorous Budd-Chiari syndrome.

Authors:  S Pelletier; B Landi; J C Piette; P Ekert; A Coutellier; C Desmoulins; J P Fadlallah; S Herson; D Valla
Journal:  J Hepatol       Date:  1994-07       Impact factor: 25.083

Review 8.  Hepatic outflow obstruction (Budd-Chiari syndrome). Experience with 177 patients and a review of the literature.

Authors:  J B Dilawari; P Bambery; Y Chawla; U Kaur; S R Bhusnurmath; H S Malhotra; G K Sood; S K Mitra; S K Khanna; B S Walia
Journal:  Medicine (Baltimore)       Date:  1994-01       Impact factor: 1.889

9.  Antithrombin III deficiency: an etiology of Budd-Chiari syndrome.

Authors:  M Das; S F Carroll
Journal:  Surgery       Date:  1985-02       Impact factor: 3.982

10.  PRV-1 mRNA expression discriminates two types of essential thrombocythemia.

Authors:  M Griesshammer; S Klippel; E Strunck; S Temerinac; U Mohr; H Heimpel; H L Pahl
Journal:  Ann Hematol       Date:  2004-03-18       Impact factor: 3.673

View more
  1 in total

1.  The JAK2 V617F Allele Burden in Latent Myeloproliferative Neoplasms Presenting with Splanchnic Vein Thrombosis.

Authors:  Matthew Goodyer; Stephen E Langabeer; Karl Haslam; Karen Murphy
Journal:  Pathol Oncol Res       Date:  2015-10-08       Impact factor: 3.201

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.